MCID: GLL008
MIFTS: 64

Gilles De La Tourette Syndrome

Categories: Rare diseases, Mental diseases

Aliases & Classifications for Gilles De La Tourette Syndrome

MalaCards integrated aliases for Gilles De La Tourette Syndrome:

Name: Gilles De La Tourette Syndrome 53 12 24 71 14 69
Tourette Syndrome 53 12 72 49 24 50 36 28 13 51 40 3 41
Gilles De La Tourette's Syndrome 72 49 24
Tourette Disorder 53 49 24
Gts 53 24 71
Ts 53 24 3
Chronic Motor and Vocal Tic Disorder 24
Motor-Verbal Tic Disorder 12
Tourette Syndrome; Ts 53
Tourette's Syndrome 49
Tourette's Disease 24
Guinon's Disease 12
Psychogenic Tics 12
Td 24

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant

Miscellaneous:
male:female ratio 4:1
onset ages 2 to 14 years


HPO:

31
gilles de la tourette syndrome:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Gilles De La Tourette Syndrome

NIH Rare Diseases : 49 Tourette syndrome is a complex neurological disorder that is characterized by repetitive, sudden, uncontrolled (involuntary) movements and sounds (vocalizations) called tics. Tourette syndrome is named for Georges Gilles de la Tourette, who first described this disorder in 1885. A variety of genetic and environmental factors likely play a role in causing Tourette syndrome. A small number of people with Tourette syndrome have been found to have mutations involving the SLITRK1 gene. The syndrome is believed to be linked to problems in certain areas of the brain, and the chemical substances (dopamine, serotonin, and norepinephrine) that help nerve cells talk to one another. It is estimated that about 1% of the population has Tourette syndrome. Many people with very mild tics may not be aware of them and never seek medical help. Tourette syndrome is four times as likely to occur in boys as in girls. Although Tourette syndrome can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood. Last updated: 3/6/2016

MalaCards based summary : Gilles De La Tourette Syndrome, also known as tourette syndrome, is related to impulse control disorder and tardive dyskinesia, and has symptoms including sleep disturbance, attention deficit hyperactivity disorder and obsessive-compulsive behavior. An important gene associated with Gilles De La Tourette Syndrome is SLITRK1 (SLIT And NTRK Like Family Member 1), and among its related pathways/superpathways are Histidine metabolism and Circadian entrainment. The drugs Clonidine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

OMIM : 53 Tourette syndrome is a neurobehavioral disorder manifest particularly by motor and vocal tics and associated with behavioral abnormalities. Tics are sudden, brief, intermittent, involuntary or semi-voluntary movements (motor tics) or sounds (phonic or vocal tics). They typically consist of simple, coordinated, repetitive movements, gestures, or utterances that mimic fragments of normal behavior. Motor tics may range from simple blinking, nose twitching, and head jerking to more complex throwing, hitting, or making rude gestures. Phonic tics include sniffling, throat clearing, blowing, coughing, echolalia, or coprolalia. Males are affected about 3 times more often than females, and onset usually occurs between 3 and 8 years of age. By age 18 years, more than half of affected individuals are free of tics, but they may persist into adulthood (review by Jankovic, 2001). (137580)

UniProtKB/Swiss-Prot : 71 Gilles de la Tourette syndrome: Neurologic disorder manifested particularly by motor and vocal tics and associated with behavioral abnormalities.

MedlinePlus : 40 If you have Tourette syndrome, you make unusual movements or sounds, called tics. You have little or no control over them. Common tics are throat-clearing and blinking. You may repeat words, spin, or, rarely, blurt out swear words. Tourette syndrome is a disorder of the nervous system. It often occurs with other problems, such as Attention deficit hyperactivity disorder (ADHD) Obsessive-compulsive disorder (OCD) Anxiety Depression The cause of Tourette syndrome is unknown. It is more common in boys than girls. The tics usually start in childhood and may be worst in the early teens. Many people eventually outgrow them. No treatment is needed unless the tics interfere with everyday life. Excitement or worry can make tics worse. Calm, focused activities may make them better. Medicines and talk therapy may also help. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Meet two families and hear about their experiences living with Attention-Deficit/Hyperactivity Disorder and Tourette Syndrome.

NINDS : 50 Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. The first symptoms of TS are almost always noticed in childhood.  Some of the more common tics include eye blinking and other vision irregularities, facial grimacing, shoulder shrugging, and head or shoulder jerking. Perhaps the most dramatic and disabling tics are those that result in self-harm such as punching oneself in the face, or vocal tics including coprolalia (uttering swear words) or echolalia (repeating the words or phrases of others).  Many with TS experience additional neurobehavioral problems including inattention, hyperactivity and impulsivity, and obsessive-compulsive symptoms such as intrusive thoughts/worries and repetitive behaviors.

Genetics Home Reference : 24 Tourette syndrome is a complex disorder characterized by repetitive, sudden, and involuntary movements or noises called tics. Tics usually appear in childhood, and their severity varies over time. In most cases, tics become milder and less frequent in late adolescence and adulthood.

Disease Ontology : 12 A tic disorder that is characterized by multiple physical (motor) tics and at least one vocal (phonic) tic present for more than a year.

Wikipedia : 72 Tourette syndrome (TS or simply Tourette\'s) is a common neuropsychiatric disorder with onset in... more...

Related Diseases for Gilles De La Tourette Syndrome

Diseases related to Gilles De La Tourette Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 30.9 DRD2 DRD4 SLITRK1
2 tardive dyskinesia 30.7 COMT DRD2
3 dystonia 30.7 DRD2 DRD5 SGCE SLC6A3
4 anxiety 30.7 BDNF COMT SLC6A3
5 obsessive-compulsive disorder 30.6 BDNF COMT DRD2 DRD4 SGCE SLC6A3
6 autism 30.5 BDNF CNTNAP2 COMT DRD2 DRD4 IMMP2L
7 tic disorder 30.4 DRD2 DRD4 DRD5 HDC IMMP2L SLC6A3
8 major depressive disorder 30.4 BDNF COMT DRD2 DRD4 SLC6A3
9 schizophrenia 29.5 ADRA2A BDNF CNTNAP2 COMT DBH DRD2
10 glanzmann thrombasthenia 11.7
11 virus-associated trichodysplasia spinulosa 11.6
12 cholestasis, progressive familial intrahepatic, 1 11.5
13 trichotillomania 11.4
14 mitochondrial dna depletion syndrome 7 11.2
15 turner syndrome 11.2
16 trichostasis spinulosa 11.1
17 tuberous sclerosis 1 11.1
18 timothy syndrome 11.1
19 cholestasis, benign recurrent intrahepatic, 1 11.1
20 temperature sensitivity complementation, cell cycle specific, k12 11.0
21 growth control, y-chromosome influenced 11.0
22 lymphoma, hodgkin, classic 10.9
23 kleefstra syndrome 10.9
24 albinism, oculocutaneous, type ib 10.8
25 tuberous sclerosis 2 10.8
26 perry syndrome 10.8
27 mitochondrial trifunctional protein deficiency 10.8
28 leukocyte adhesion deficiency, type iii 10.8
29 adenine phosphoribosyltransferase deficiency 10.8
30 undifferentiated pleomorphic sarcoma 10.8
31 mutism 10.5 CNTNAP2 SLC6A3
32 alcohol-induced mental disorder 10.5 DRD2 SLC6A3
33 schizophreniform disorder 10.5 COMT DRD2
34 polysubstance abuse 10.5 COMT DRD2
35 pathological gambling 10.5 DRD2 DRD4 SLC6A3
36 delusional disorder 10.5 DRD2 DRD4
37 cocaine abuse 10.4 DBH DRD2 SLC6A3
38 antisocial personality disorder 10.4 COMT DRD2 SLC6A3
39 cocaine dependence 10.4 DBH DRD2 SLC6A3
40 multiple system atrophy 1 10.4 DBH DRD2 SLC6A3
41 migraine with aura 10.4 DBH DRD2 SLC6A3
42 chronic tic disorder 10.4
43 dystonia 11, myoclonic 10.4 DBH DRD2 SGCE
44 tobacco addiction 10.4 COMT DRD2 SLC6A3
45 alcoholic psychosis 10.4 DRD2 SLC6A3
46 focal dystonia 10.4 DRD2 DRD5 SGCE
47 stuttering 10.4 CNTNAP2 DBH DRD2 SLC6A3
48 traumatic brain injury 10.4 BDNF COMT DRD2
49 movement disease 10.3 DRD2 SGCE SLC6A3
50 brain injury 10.3 BDNF COMT DRD2

Graphical network of the top 20 diseases related to Gilles De La Tourette Syndrome:



Diseases related to Gilles De La Tourette Syndrome

Symptoms & Phenotypes for Gilles De La Tourette Syndrome

Symptoms via clinical synopsis from OMIM:

53
Neurologic Central Nervous System:
sleep disturbance
obsessive-compulsive behavior
aggressive behavior
echolalia
coprolalia
more

Clinical features from OMIM:

137580

Human phenotypes related to Gilles De La Tourette Syndrome:

31 (show all 8)
# Description HPO Frequency HPO Source Accession
1 sleep disturbance 31 HP:0002360
2 attention deficit hyperactivity disorder 31 HP:0007018
3 obsessive-compulsive behavior 31 HP:0000722
4 aggressive behavior 31 HP:0000718
5 echolalia 31 HP:0010529
6 self-mutilation 31 HP:0000742
7 motor tics 31 HP:0100034
8 phonic tics 31 HP:0100035

UMLS symptoms related to Gilles De La Tourette Syndrome:


sleeplessness, vertigo/dizziness, chronic pain, tremor, syncope, sleep disturbances, seizures, sciatica, pain, headache, back pain, athetosis

MGI Mouse Phenotypes related to Gilles De La Tourette Syndrome:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 SLC6A3 SLITRK1 ADRA1A ADRA2A BDNF BTBD9
2 homeostasis/metabolism MP:0005376 9.93 HDC HMBS SLC6A3 SLITRK1 ADRA1A ADRA2A
3 nervous system MP:0003631 9.8 ADRA2A BDNF BTBD9 CNTNAP2 COMT DBH
4 taste/olfaction MP:0005394 8.92 BDNF CNTNAP2 DRD2 SLC6A3

Drugs & Therapeutics for Gilles De La Tourette Syndrome

Drugs for Gilles De La Tourette Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 156)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4 4205-90-7 2803
2
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
3
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
4 Piracetam Approved, Investigational Phase 4 7491-74-9
5
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
6
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
7
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
8
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 5324346 3404
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Ondansetron Approved Phase 4 99614-02-5 4595
12
Galantamine Approved Phase 4 357-70-0 9651
13
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
14 Etiracetam Investigational Phase 4 33996-58-6
15 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Adrenergic Agonists Phase 4,Phase 3
17 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
18 Adrenergic alpha-Agonists Phase 4,Phase 3
19 Analgesics Phase 4,Phase 3
20 Antihypertensive Agents Phase 4,Phase 3
21 Autonomic Agents Phase 4,Phase 1
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
24 Sympatholytics Phase 4
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2
26 Cholinergic Agents Phase 4
27 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
28 Excitatory Amino Acid Agonists Phase 4
29 Excitatory Amino Acid Antagonists Phase 4
30 Excitatory Amino Acids Phase 4
31 Neuroprotective Agents Phase 4,Phase 3
32 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antipsychotic Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2
35 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Nootropic Agents Phase 4
37 Anti-Anxiety Agents Phase 4
38 Antidepressive Agents Phase 4
39 Antidepressive Agents, Second-Generation Phase 4
40 Antiemetics Phase 4
41 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
43 Cytochrome P-450 Enzyme Inhibitors Phase 4
44 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
45 Dopamine Antagonists Phase 4,Phase 3,Phase 1,Phase 2
46 Gastrointestinal Agents Phase 4
47 Haloperidol decanoate Phase 4
48 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 1
49
Serotonin Phase 4,Phase 2 50-67-9 5202
50 Serotonin Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 139)

# Name Status NCT ID Phase Drugs
1 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
2 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
3 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
4 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
5 Guanfacine in Children With Tic Disorders Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
6 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
7 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
8 Safety Study of Galantamine in Tic Disorders Terminated NCT00226824 Phase 4 galantamine
9 Pallidal Stimulation and Gilles de la Tourette Syndrome Completed NCT00478842 Phase 3
10 Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01416441 Phase 3 aripiprazole
11 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418352 Phase 3 aripiprazole 52.5 mg;Matching Placebo;Aripiprazole 77.5 mg;Aripiprazole 110 mg
12 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01418339 Phase 3 aripiprazole;Placebo
13 Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
14 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
15 A Randomized, Placebo-controlled, Tourette Syndrome Study. Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
16 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome. Completed NCT00206336 Phase 3 Topiramate (drug)
17 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
18 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
19 Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children Completed NCT00218777 Phase 2, Phase 3
20 Phase III Study of 5LGr to Treat Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
21 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
22 Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. Recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
23 Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome Recruiting NCT03066193 Phase 3 Dronabinol
24 CANNAbinoids in the Treatment of TICS (CANNA-TICS) Not yet recruiting NCT03087201 Phase 3 nabiximols;placebo
25 Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome Terminated NCT00681863 Phase 3 pramipexole 0.125 mg BID;pramipexole 0.0625 mg QD;pramipexole 0.125 mg TID;pramipexole 0.25 mg BID;pramipexole 0.0625 mg BID
26 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Unknown status NCT02112253 Phase 1, Phase 2
27 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2 smoking of cannabis;smoking cigarettes with placebo
28 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
29 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
30 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Completed NCT02581865 Phase 2 NBI-98854;Placebo
31 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome Completed NCT02679079 Phase 2 NBI-98854;Placebo
32 VoIP Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
33 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
34 A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome Completed NCT02217007 Phase 2 SNC-102 sustained release tablet
35 A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome Completed NCT01647269 Phase 2
36 Thalamic Deep Brain Stimulation for Tourette Syndrome Completed NCT00311909 Phase 2
37 Subthalamic Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
38 N-acetylcysteine (NAC) for Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
39 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria Completed NCT00558467 Phase 2 pramipexole immediate release (IR);Placebo
40 Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome Completed NCT00529308 Phase 2
41 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome Completed NCT02879578 Phase 2 NBI-98854
42 Effectiveness of Behavior Therapy and Psychosocial Therapy for the Treatment of Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
43 Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome Completed NCT00004393 Phase 2 risperidone
44 Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome Completed NCT00004652 Phase 2 pimozide
45 Safety and Efficacy of Cannabis in Tourette Syndrome Recruiting NCT03247244 Phase 2 Cannabis;Cannabis;Cannabis
46 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Recruiting NCT03325010 Phase 2 Valbenazine;Placebo oral capsule
47 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Active, not recruiting NCT02102698 Phase 2 Ecopipam
48 Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome Enrolling by invitation NCT03444038 Phase 2 NBI-98854
49 FAAH Inhibitor Trial for Adults With Tourette Syndrome Suspended NCT02134080 Phase 2 PF-04457845;Placebo
50 Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome Terminated NCT01043549 Phase 2

Search NIH Clinical Center for Gilles De La Tourette Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: tourette syndrome

Genetic Tests for Gilles De La Tourette Syndrome

Genetic tests related to Gilles De La Tourette Syndrome:

# Genetic test Affiliating Genes
1 Tourette Syndrome 28 HDC SLITRK1

Anatomical Context for Gilles De La Tourette Syndrome

MalaCards organs/tissues related to Gilles De La Tourette Syndrome:

38
Brain, Eye, Cortex, Globus Pallidus, Thalamus, Bone, Colon

Publications for Gilles De La Tourette Syndrome

Articles related to Gilles De La Tourette Syndrome:

(show top 50) (show all 520)
# Title Authors Year
1
Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. ( 29154107 )
2018
2
Toward a Symptom-Guided Neurostimulation for Gilles de la Tourette Syndrome. ( 28289393 )
2017
3
Pathological glutamatergic neurotransmission in Gilles de la Tourette syndrome. ( 28007998 )
2017
4
Gilles de la Tourette syndrome. ( 28150696 )
2017
5
Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. ( 28738196 )
2017
6
Parental Psychopathology and Tourette Syndrome/Chronic Tic Disorder in Offspring: A Nationwide Case-Control Study. ( 28335873 )
2017
7
Thirty first annual symposium on etiology, pathogenesis, and treatment of Parkinson disease and other movement disorders: Presented by the Parkinson study group, huntington study group, dystonia study group, tourette syndrome study group, cooperative ataxia group, and tremor research group. ( 28887904 )
2017
8
Pediatric Tourette Syndrome: A Tic Disorder with a Tricky Presentation. ( 28611559 )
2017
9
Altered topology of structural brain networks in patients with Gilles de la Tourette syndrome. ( 28878322 )
2017
10
Putting the Pieces Together in Gilles de la Tourette Syndrome: Exploring the Link Between Clinical Observations and the Biological Basis of Dysfunction. ( 27783238 )
2017
11
Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome. ( 28740149 )
2017
12
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients. ( 28796166 )
2017
13
Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder. ( 28574423 )
2017
14
Antipsychotic-induced hyperprolactinemia in Tourette syndrome. ( 28740637 )
2017
15
Gilles de la Tourette syndrome. ( 28150698 )
2017
16
Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome. ( 28641109 )
2017
17
Cognitive flexibility and its electrophysiological correlates in Gilles de la Tourette syndrome. ( 28863370 )
2017
18
Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. ( 28445405 )
2017
19
Editorial: The Neurobiology and Genetics of Gilles de la Tourette Syndrome: New Avenues through Large-Scale Collaborative Projects. ( 29075205 )
2017
20
Gilles de la Tourette Syndrome, Depression, Depressive Illness, and Correlates in a Child and Adolescent Population. ( 28099039 )
2017
21
A tug of war: antagonistic effective connectivity patterns over the motor cortex and the severity of motor symptoms in Gilles de la Tourette syndrome. ( 28833746 )
2017
22
Altered perceptual binding in Gilles de la Tourette syndrome. ( 27544346 )
2016
23
Investigation of a Possible Role for the Histidine Decarboxylase Gene in Tourette Syndrome in the Chinese Han Population: A Family-Based Study. ( 27529419 )
2016
24
The English Version of the Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL): A Validation Study in the United Kingdom. ( 27686095 )
2016
25
Deep brain stimulation in Gilles de la Tourette syndrome: killing several birds with one stone? ( 27746910 )
2016
26
Aripiprazole Improves Associated Comorbid Conditions in Addition to Tics in Adult Patients with Gilles de la Tourette Syndrome. ( 27672358 )
2016
27
The relationship between tics, OC, ADHD and autism symptoms: A cross- disorder symptom analysis in Gilles de la Tourette syndrome patients and family-members. ( 26826899 )
2016
28
Impact of Perceived Stress, Anxiety-Depression and Social Support on Coping Strategies of Parents Having A Child With Gilles de la Tourette Syndrome. ( 26804511 )
2016
29
The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work? ( 27199634 )
2016
30
TS-EUROTRAIN: A European-Wide Investigation and Training Network on the Etiology and Pathophysiology of Gilles de la Tourette Syndrome. ( 27601976 )
2016
31
Lack of genetic association of 5-HTR2A 102 T/C and -1438A/G polymorphisms with Tourette syndrome in a family-based association study in a Chinese Han population. ( 25858583 )
2016
32
A preliminary examination of self-concept in older adolescents and young adults with Gilles de la Tourette syndrome. ( 28017555 )
2016
33
Temporal relationship between premonitory urges and tics in Gilles de la Tourette syndrome. ( 26922503 )
2016
34
Microglial Dysregulation in OCD, Tourette Syndrome, and PANDAS. ( 28053994 )
2016
35
Health-related quality of life, anxiety and depression in parents of adolescents with Gilles de la Tourette syndrome: a controlled study. ( 27942998 )
2016
36
BDNF and LTP-/LTD-like plasticity of the primary motor cortex in Gilles de la Tourette syndrome. ( 27900437 )
2016
37
Deutetrabenazine in Tics Associated with Tourette Syndrome. ( 27917309 )
2016
38
Gilles de la Tourette syndrome is associated with hypermethylation of the dopamine D2 receptor gene. ( 27883923 )
2016
39
Tetrabenazine-induced oculogyric crisis - a rare complication in the treatment of Gilles de la Tourette syndrome. ( 26955276 )
2016
40
Deep Brain Stimulation in Gilles de la Tourette Syndrome: What Does the Future Hold? A Cohort of 48 Patients. ( 26348012 )
2016
41
Illusion of agency in patients with Gilles de la Tourette Syndrome. ( 26963083 )
2016
42
New Insights into Clinical Characteristics of Gilles de la Tourette Syndrome: Findings in 1032 Patients from a Single German Center. ( 27672357 )
2016
43
Investigation of SNP rs2060546 Immediately Upstream to NTN4 in a Danish Gilles de la Tourette Syndrome Cohort. ( 27920664 )
2016
44
The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. ( 26880181 )
2016
45
Health-related quality of life in patients with Gilles de la Tourette syndrome at the transition between adolescence and adulthood. ( 27457656 )
2016
46
Association between the polymorphism of C861G (rs6296) in the serotonin 1B receptor gene and Tourette syndrome in Han Chinese people. ( 26123080 )
2015
47
rs2043211 polymorphism in CARD8 is not associated with Tourette syndrome in a family-based association study in the Chinese Han population. ( 25921775 )
2015
48
Alterations in structural connectivity may contribute both to the occurrence of tics in Gilles de la Tourette syndrome and to their subsequent control. ( 25627236 )
2015
49
Association between DRD2/ANKK1 TaqIA Polymorphism and Susceptibility with Tourette Syndrome: A Meta-Analysis. ( 26110876 )
2015
50
Narcissistic vulnerability is a common cause for depression in patients with Gilles de la Tourette syndrome. ( 26548979 )
2015

Variations for Gilles De La Tourette Syndrome

ClinVar genetic disease variations for Gilles De La Tourette Syndrome:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 HDC NM_002112.3(HDC): c.951G> A (p.Trp317Ter) single nucleotide variant Pathogenic rs267606861 GRCh37 Chromosome 15, 50544717: 50544717
2 SLITRK1 NM_052910.2(SLITRK1): c.1264delC (p.Leu422Phefs) deletion Pathogenic rs193302861 GRCh37 Chromosome 13, 84454379: 84454379
3 SLITRK1 NM_052910.2(SLITRK1): c.*689G> A single nucleotide variant Pathogenic rs191284403 GRCh37 Chromosome 13, 84452863: 84452863

Copy number variations for Gilles De La Tourette Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 60595 11 88300000 92800000 Copy number GRM5 Tourette syndrome
2 97401 16 1 7900000 Copy number A2BP1 Tourette syndrome
3 107550 17 15900000 22100000 Microdeletion Tourette syndrome
4 161233 22 17900000 22200000 Duplication COMT Tourette syndrome
5 204047 6 105500000 114600000 Copy number NKAIN2 Tourette syndrome
6 218083 7 107400000 127100000 Copy number IMMP2L Tourette syndrome
7 221370 7 143100000 147900000 Copy number CNTNAP2 Tourette syndrome
8 222485 7 152600000 155100000 Copy number DPP6 Tourette syndrome
9 257157 X 1 4300000 Deletion NLGN4 Tourette syndrome

Expression for Gilles De La Tourette Syndrome

Search GEO for disease gene expression data for Gilles De La Tourette Syndrome.

Pathways for Gilles De La Tourette Syndrome

Pathways related to Gilles De La Tourette Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Histidine metabolism hsa00340

GO Terms for Gilles De La Tourette Syndrome

Cellular components related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.56 ADRA1A ADRA2A DRD2 DRD4 DRD5 HTR3B
2 integral component of membrane GO:0016021 9.5 AADAC ADRA1A ADRA2A CNTNAP2 COMT DBH
3 axon GO:0030424 9.46 CNTNAP2 COMT DRD2 SLC6A3

Biological processes related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 ADRA1A COMT DRD2 SLC6A3
2 locomotory behavior GO:0007626 9.79 DBH DRD2 SLC6A3
3 learning GO:0007612 9.74 CNTNAP2 COMT DRD5
4 synapse assembly GO:0007416 9.73 BDNF DRD2 SLITRK1
5 response to cocaine GO:0042220 9.7 DRD2 DRD5 SLC6A3
6 negative regulation of adenylate cyclase activity GO:0007194 9.69 ADRA2A DRD2 DRD4
7 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD4
8 modulation of chemical synaptic transmission GO:0050804 9.66 BTBD9 DRD2
9 response to iron ion GO:0010039 9.66 DRD2 SLC6A3
10 response to pain GO:0048265 9.65 COMT DBH
11 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD5
12 transmission of nerve impulse GO:0019226 9.64 CNTNAP2 DRD5
13 negative regulation of protein secretion GO:0050709 9.64 DRD2 DRD4
14 negative regulation of cAMP biosynthetic process GO:0030818 9.63 ADRA2A DRD4
15 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD2 DRD5
16 negative regulation of voltage-gated calcium channel activity GO:1901386 9.62 DRD2 DRD4
17 prepulse inhibition GO:0060134 9.61 DRD2 SLC6A3
18 striatum development GO:0021756 9.61 CNTNAP2 DRD2
19 adult behavior GO:0030534 9.61 CNTNAP2 DRD2 SLITRK1
20 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.6 DRD2 DRD4
21 regulation of dopamine metabolic process GO:0042053 9.59 DRD4 SLC6A3
22 adenohypophysis development GO:0021984 9.58 DRD2 SLC6A3
23 adrenergic receptor signaling pathway GO:0071875 9.58 ADRA1A ADRA2A
24 associative learning GO:0008306 9.58 DBH DRD2 DRD5
25 catecholamine biosynthetic process GO:0042423 9.55 DBH HDC
26 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 9.54 ADRA1A DRD5
27 dopamine receptor signaling pathway GO:0007212 9.54 DRD2 DRD4 DRD5
28 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.5 ADRA1A ADRA2A DRD2
29 fear response GO:0042596 9.49 DBH DRD4
30 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.48 DRD2 DRD4
31 response to histamine GO:0034776 9.46 DRD2 DRD4
32 behavioral response to ethanol GO:0048149 9.43 DBH DRD2 DRD4
33 dopamine metabolic process GO:0042417 9.33 COMT DRD2 DRD4
34 dopamine catabolic process GO:0042420 9.13 COMT DBH SLC6A3
35 response to amphetamine GO:0001975 8.92 DBH DRD2 DRD4 DRD5

Molecular functions related to Gilles De La Tourette Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.72 ADRA1A ADRA2A DRD2 DRD4 DRD5
2 drug binding GO:0008144 9.61 DRD2 DRD4 SLC6A3
3 epinephrine binding GO:0051379 9.4 ADRA2A DRD4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.37 DRD2 DRD4
5 adrenergic receptor activity GO:0004935 9.33 ADRA1A ADRA2A DRD2
6 norepinephrine binding GO:0051380 9.26 ADRA2A DRD4
7 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
8 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Gilles De La Tourette Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....